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Background—In a number of coronary bifurcation lesions, both the main vessel and the side branch need stent coverage.
Using sirolimus eluting stents, we compared 2 dedicated bifurcation stent techniques, the crush and the culotte
techniques in a randomized trial with separate clinical and angiographic end-points.
Methods and Results—A total of 424 patients with a bifurcation lesion were randomized to crush (n209) and culotte
(n215) stenting. The primary end point was major adverse cardiac events; cardiac death, myocardial infarction, target
vessel revascularization, or stent thrombosis after 6 months. At 6 months there were no significant differences in major
adverse cardiac event rates between the groups; crush 4.3%, culotte 3.7% (P0.87). Procedure and fluoroscopy times
and contrast volumes were similar in the 2 groups. The rates of procedure-related increase in biomarkers of myocardial
injury were 15.5% in crush versus 8.8% in culotte group (P0.08). A total of 324 patients had a quantitative coronary
assessment at the index procedure and after 8 months. The angiographic end-points of in-segment and in-stent restenosis
of main vessel and/or side branch after 8 months were found in 12.1% versus 6.6% (P0.10) and in 10.5% versus 4.5%
(P0.046) in the crush and culotte groups, respectively.
Conclusions—Both the crush and the culotte bifurcation stenting techniques were associated with similar and excellent
clinical and angiographic results. Angiographically, there was a trend toward less in-segment restenosis and significantly
reduced in-stent restenosis following culotte stenting. (Circ Cardiovasc Intervent. 2009;2:27-34.)
Key Words: stents  drugs  sirolimus  restenosis  bifurcation
Bifurcation lesions occur in about 15% of percutaneouscoronary interventions (PCI).1 In these lesions, balloon
angioplasty without stenting had a high risk of acute vessel
closure.2 Furthermore, implantation of bare metal stents
(BMS) was associated with over 30% rate of major adverse
cardiac events (MACE) at 1 year in a registry study.3 Another
study found over 30% rate of target lesion revascularization
at 6 months follow-up both with 1 and 2 BMS techniques.4
The use of sirolimus eluting stents (SES) has been reported to
reduce restenosis in simple and in complicated coronary
lesions.5–10 SES implantation in bifurcation lesions has been
very promising with low clinical and angiographic event
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rates, both after procedures with stenting of the main vessel
(MV) only and in procedures where both MV and side branch
(SB) were stented.5,11,12 At present, the general recommended
stenting strategy in coronary bifurcation lesions is the provi-
sional SB stenting strategy.13 With this strategy, the MV is
stented, whereas the SB is only treated with stent implanta-
tion in case of significant residual SB stenosis after stenting
of the MV. However, a number of coronary bifurcation
lesions need stent treatment of both the SB and the MV.
Therefore, to provide stent coverage of the entire bifurcation
region, dedicated bifurcation stent techniques have been
proposed. Among those, the crush14 and the culotte15 tech-
niques are currently used in clinical practice and have been
associated with promising clinical and angiographic out-
come.11,16 The present study is the first randomized clinical
and angiographic comparison of the crush and the culotte
bifurcation stent techniques.
Methods
Patients and Study Design
This nonblinded randomized multicenter trial was conducted at 13
cardiology centers in Denmark, Finland, Norway, and Latvia. From
August 2005 to February 2007 a total of 424 patients were enrolled.
On the basis of the total PCI volumes of the participating centers, the
number of eligible patients was estimated to 2292 patients. The
primary reason for not enrolling in the study was differences in
inclusion rates among operators. A flow diagram of the study is
shown in Figure 1. Ethics committees in all participating countries
approved the protocol, and all participating patients gave written
informed consent.
Men and women, aged 18 years or older, with stable or unstable
angina pectoris or silent ischemia and a de novo coronary bifurcation
lesion were considered eligible for enrolment. A bifurcation lesion
was defined according to Lefevre et al17 and could be located in the
left anterior descending artery and a diagonal, the circumflex artery
and an obtuse marginal, the right coronary artery and posterior
descending artery/postero-lateral artery or the left main stem/circum-
flex artery/left anterior descending artery in a right dominant system.
The diameter of MV had to be 3.0 mm and of SB 2.5 mm by
visual estimate. Exclusion criteria were ST-elevation acute myocar-
dial infarction (AMI) within 24 hours, life expectancy less than one
year, s-creatinine 200 mol/L and allergy to any of the drugs used
(aspirin, clopidogrel, ticlopidine, sirolimus, and paclitaxel).
Randomization
Randomization was performed in blocks for each participating
hospital, 1:1 by computerized assignment with stratification accord-
ing to sex, diabetes, age 70 years, use of glycoprotein receptor
antagonists, and consent to angiographic follow-up. An automatic
telephone randomization/voice-response system was used. Patients
were randomized before any balloon dilatation was performed.
Stent Implantation
Patients were pretreated with aspirin (75 mg) and clopidogrel (300
mg). Heparin was administrated according to local hospital routine,
and ACT control was not mandatory. Glycoprotein receptor antag-
onists were used at the discretion of the operator. Aspirin was
continued indefinitely, clopidogrel for 6 to 12 months according to
local practice. Ticlopidine could be used if the patient did not tolerate
clopidogrel.
The operator was requested to avoid pretreatment (conventional
balloon or cutting balloon) of segments not covered by stent. The
SES, “Cypher Select” coronary stent (Cordis/Johnson & Johnson,
Miami Lakes, Fla) was used in the study.
Main treatment principles of the crush technique are as follows:
(1) wiring of MV and SB, (2) optional predilatation of MV and/or
SB, (3) stenting of SB with uninflated stent or balloon in MV and
with proximal end of SB stent at the center of the MV, (4) SB wire
and stent balloon removed, (5) crushing of SB stent with MV balloon
or stent, (6) in balloon crush, stenting of MV and rewiring of SB
through MV stent, and (7) procedure finalized by kissing balloon
dilatation.
Main treatment principles of the culotte technique are as follows:
(1) wiring of MV and SB, (2) optional predilatation of MV and/or
SB, (3) stenting of MV, (4) rewiring of SB through MV stent, (5)
stenting of SB through MV stent, (6) rewiring of MV through SB
stent, and (7) procedure finalized by kissing balloon dilatation.
Implantation of additional stents to cover the whole lesion or to
cover a dissection was allowed. If the study stent could not be
delivered, another drug eluting stent or a BMS was allowed.
Different types of drug eluting stents in the same vessel were not
allowed. Both operator and patient were aware of the assigned
treatment.
Cardiac Biomarkers and ECG
CK-MB mass, Troponin-T or Troponin-I were measured at the time
of the procedure and after 12 to 18 hours. Troponin-T was used as
Figure 1. Flow diagram of the Nordic
Bifurcation Stent Technique Study. The
number of eligible patients was an esti-
mate based the total PCI volume of the
participating centers. FU, follow-up.
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the primary marker, CK-MB mass or Troponin-I only if Troponin-T
was not available. To avoid confounding nonprocedure-related
marker elevation, patients with unstable angina pectoris were in-
cluded in the biomarker analysis only if preprocedure and postpro-
cedure markers were normal. Marker elevation of more than or equal
to 3 times upper limit of normal was considered significant. A 12
lead ECG was obtained before and 12 to 18 hours after the
procedure.
Follow-Up
For safety reasons, total death and MACE were recorded by telephone
call after 1 month. There was a clinical follow-up visit after 6 months for
primary end-point registration. An 8-month control coronary angiogra-
phy was scheduled at randomization in patients who consented herein.
No patients were lost to clinical follow-up.
Quantitative Coronary Angiography at
Eight Months
Coronary angiograms obtained at baseline, at completion of the
stenting procedure, and after 8 months, were submitted to 1 of the 2
angiographic core laboratories (Aarhus University Hospital, Skejby,
Aarhus, Denmark or Paul Stradins Clinical Hospital, Riga, Latvia)
and were analyzed with the use of a computer-based system
dedicated to bifurcation analysis (Qangio XA version 7.0, Medis,
Leiden, The Netherlands). Quantitative angiographic measurements
of the bifurcation lesion were obtained in the following 3 segments:
the proximal MV segment, the distal MV segment, and the SB. In the
MV and the SB segments, measurements were obtained in the stents
and in the margins 5-mm proximal and distal to the stents (edge).
The analyses were not blinded.
Definitions
Total death; death for any reason. Cardiac death; death was consid-
ered cardiac unless other cause documented. Nonprocedure-related
MI, a rise of biochemical markers exceeding the decision limit of
myocardial infarction (above the 99th percentile) for a reference
population provided an coefficient of variation of 10%) with at
least one of the following: (1) ischemic symtomps; (2) ECG changes
indicative of ischemia (ST segment elevation or depression; (3)
development of pathological Q-wave; and (4) no relation to a PCI
procedure. Stent thrombosis (definite, possible, and probable) was
defined according to the ARC criteria.18 Target lesion revasculariza-
tion is defined as repeated revascularization by PCI or surgery of the
target lesion. Target vessel revascularization is defined as repeated
revascularization by PCI or surgery of the target vessel. Percent
diameter stenosis is calculated as (reference diameterminimal
luminal diameter)/reference diameter100. Restenosis is 50%
diameter stenosis at 8 months angiographic follow-up. Late lumen
loss is postprocedure minimal luminal diameterminimal luminal
diameter in millimeters at 8 months follow-up. Procedural success is
residual stenosis 30% and TIMI flow III in MV and SB after the
index procedure.
Study End-Points
The primary end-point of the study was the clinical combined
end-point of MACE; cardiac death, nonprocedure-related myocardial
infarction, stent thrombosis, or target vessel revascularization by PCI
or coronary artery bypass surgery after 6 months.
Secondary end-points were as follows: (1) individual end-points of
total death, cardiac death, nonprocedure-related myocardial infarc-
tion, target lesion revascularization, and target vessel revasculariza-
tion; (b) procedure-related biomarker increase (rise of biochemical
markers exceeding 3 times the decision limit of myocardial
infarction [99th percentile including 10% cardiovascular] of Cre-
atine Kinase-MB (CK-MB) mass, Troponin-T, and/or Troponin-I);
(c) the angiographic end-point of significant in-segment and in-stent
restenosis (50% diameter stenosis) of MV and/or SB. The study
was monitored by the PCI-Research Unit, Aarhus University Hos-
pital, Skejby. An independent end-point committee, chaired by
Kristian Thygesen, MD, Aarhus University Hospital, Aarhus, Den-
mark adjudicated the clinical study end-points blindly.
Statistical Analysis
Power calculations of the present study were problematic because
there were no available clinical end-point data on culotte stenting and
limited data on crush stenting using DES. We based our power
calculations on an expected primary end-point event rate of 25% in
the culotte group, alpha 5%, power 80%, and using a 2-sided 2 test.
To detect a reduction in primary end-point rate to 13%, 167 patients
would be needed in each group. Because of considerable uncertainty
in expected end-point rates in drug-eluting stents (DES)-treated
bifurcation lesions, it was decided to include 200 patients in each
group.5 Differences in categorical variables between the 2 groups
were analyzed using the 2 test or Fisher’s exact test. Continuous
variables were analyzed using the Student’s t test and time to event
data using the Kaplan-Meier method and the log-rank test. All
probability values were 2-sided. Level of significance was 5%. The
analysis was performed on an intention to treat basis. All analyses
were performed using SPSS 13.0 (SPSS Inc, Chicago, Ill).
Statement of Responsibility
The authors had full access to the data and take full responsibility for
its integrity. All authors have read and agree to the manuscript
as written.
Results
Baseline Characteristics and Procedural Data
The 2 groups were well balanced regarding baseline clinical
characteristics and risk factors with the exception that more
patients in the crush group were treated for hypercholester-
olemia. In three fourths of the cases, the indication for
treatment was stable angina pectoris and in one fourth
unstable angina pectoris. In few patients the indication was
silent ischemia. The use of aspirin, clopidogrel, and glycopro-
tein IIb/IIIa inhibitors was similar in the 2 groups (Table 1).
Procedural data are shown in Table 2. The index lesion
Table 1. Baseline Clinical Characteristics
Crush
n209
Culotte
n215 P
Age, years 6510 6511 0.64
Male 149 (71%) 154 (72%) 1.00
Current smoker 42 (20%) 58 (27%) 0.11
Hypercholesterolemia 176 (84%) 159 (74%) 0.01
Hypertension 130 (62%) 129 (60%) 0.69
Diabetes mellitus 28 (13%) 31 (15%) 0.78
Family history 118 (57%) 134 (62%) 0.28
Prior PCI 84 (40%) 72 (34%) 0.16
Prior CABG 8 (4%) 11 (5%) 0.64
Indication
Stable angina pectoris 162 (78%) 155 (72%) 0.22
Unstable angina pectoris 43 (21%) 54 (26%) 0.30
Silent ischemia 4 (2%) 6 (3%) 0.75
Antiplatelet therapy
Aspirin 207 (99.05%) 214 (99.5%) 0.61
Clopidogrel 208 (99.5%) 215 (100%) 0.49
GP IIb/IIIa inhibitors 106 (51%) 105 (51%) 0.92
Values are mean1 SD or n (%). Fisher’s exact test or Student’s t test were
used.
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location was the left anterior descending artery in 64%, the
circumflex artery in 20%, the right coronary artery in 6%, and
the left main stem in 10%, with no difference between the
groups. There were more patients with significant stenosis in
both MV and SB, ie, a “true” bifurcation lesion (Medina
classification 1,1,1; 1,0,1; 0,1,1),19 in the culotte group than in
the crush group (82.3% versus 73.3%, P0.03). The SB had
no significant stenosis in 13.0% of crush patients versus
18.6% of culotte patients (ns). Vessel size and stenosis
severity as assessed by the operator were similar in the 2
study groups. SB angulation of 70° was seen in 64.4%,
calcification in 26.9%, and proximal tortuosity in 5.8% of the
lesions, with no difference between the groups. Procedure
time, fluoroscopy time, and volume of contrast used were
similar in the 2 groups. Also, the number of stents implanted
in the index lesion, the rate of stenting of MV and SB,
treatment success rate and rate of treatment according to
randomization were similar in the 2 groups (Table 2). The SB
was predilated more often in culotte-stented lesions. A final
kissing balloon dilatation was performed in significantly less
of the patients in the crush than in the culotte group (Table 2).
Cypher Select was the study of stent. Few other stents were
used; another drug eluting stent was implanted in 3.3% and
2.1% and a BMS in 2.5% and 1.5%, in the MV and in the SB,
respectively, with no difference between the study groups.
Clinical Outcome
The rate of event free survival for the primary end-point,
MACE (cardiac death, MI, target vessel revascularization,
stent thrombosis) after 6 months follow-up is shown in Figure
2. There was no significant difference in the 6-month MACE
rate between the 6 groups (4.3% in the crush and 3.7% in the
culotte group, P0.87). The individual end-points after 6
months are shown in Table 3. The rates of individual end
points were low in both groups without significant difference
between the groups.
Procedure-Related Elevation of Biomarkers
Procedure-related biomarker release could be evaluated in
296 patients (148 patients in both groups). A marker elevation
exceeding 3 times the decision limit of myocardial infarction
was seen in 15.5% of crush-stented patients and in 8.8% of
culotte-stented patients (P0.08).
Quantitative Coronary Angiography Analysis
At randomization, 373 patients were scheduled for an
8-month follow-up angiography. Complete angiographic
evaluation was available in 324 (88%) patients; of these, 160
patients were randomized to crush and 164 patients to culotte
Table 2. Procedural Characteristics
Crush
n209
Culotte
n215 P
LVEF (%) 5711 5712 1.00
Lesion location
Left anterior descending artery 132 (63%) 142 (66%) 0.54
Circumflex artery 42 (20%) 43 (20%) 1.00
Right coronary artery 15 (7%) 9 (4%) 0.21
Left main stem 20 (10%) 21 (10%) 1.00
Mean lesion length,* mm
Main vessel 17.410.3 17.410.1 0.93
Side branch 7.35.8 7.56.0 0.76
Mean stent length,* mm
Main vessel 23.59.3 23.69.2 0.93
Side branch 10.65.6 10.65.8 0.96
Proximal reference diameter,* mm
Main vessel 3.380.38 3.320.33 0.07
Side branch 2.780.33 2.770.33 0.77
Main vessel stented 209 (100%) 213 (99.1%) 0.50
Side branch stented 207 (99.0%) 210 (97.7%) 0.45
No. stents, n
Main vessel 1.230.44 1.200.47 0.50
Side branch 1.030.24 1.040.28 0.61
Predilatation
Main vessel 151 (72%) 158 (74%) 0.82
Side branch 123 (59%) 147 (68%) 0.04
Final kissing balloon dilatation 177 (85%) 197 (92%) 0.03
Treatment according to randomization 202 (97%) 208 (97%) 1.00
Procedural success 205 (98%) 210 (98%) 1.00
Procedure time, min 7439 7228 0.70
Fluoroscopy time, min 2215 2214 0.74
Contrast volume, mL 276104 283117 0.53
Values are mean1 SD or n (%). Fisher’s exact test or Student’s t test were
used.
*By visual estimate.
LVEF indicates left ventricular ejection fraction.
Figure 2. Cumulated MACE rate (cardiac death, MI, target ves-
sel revascularization, stent thrombosis) during 6 months follow-
up. MACE rates after 6 months; crush 4.3%, culotte 3.7%
(P0.87). The log-rank test was used.
Table 3. Individual End Points After 6 Months
Crush n209 Culotte n215 P
Total death 2 (1.0%) 1 (0.5%) 0.62
Cardiac death 2 (1.0%) 1 (0.5%) 0.62
Myocardial infarction 4 (1.9%) 3 (1.4%) 0.72
Stent thrombosis 3 (1.4%) 4 (1.9%) 0.73
Target lesion revascularization 5 (2.4%) 6 (2.8%) 0.77
Target vessel revascularization 5 (2.4%) 6 (2.8%) 0.77
Values are n (%). Fisher’s exact test was used.
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stenting. A major reason for not having 8 months angio-
graphic follow-up was the extremely long distances to inter-
ventional centers in the northern part of Scandinavia. In-
segment and in-stent QCA data (reference diameter, minimal
luminal diameter, percentual stenosis, and late loss) were
similar in the 2 groups (Table 4). There was a trend to less
in-segment restenosis at 8-month follow-up (Figure 3) be-
cause of significantly reduced SB in-stent restenosis in
culotte-treated patients (Table 4). In-stent restenosis of MV
and/or SB after 8 months was found in 10.5% versus 4.5%
(P0.046) in the crush and culotte groups, respectively.
Discussion
In this first randomized comparison of the crush and the
culotte bifurcation stenting techniques using SES, we found
low and similar 6-month clinical event rates in both study
groups. At 8-month angiographic follow-up, rates of in-lesion
restenosis were low in both groups. There was a trend toward
less restenosis of the entire bifurcation lesion because of
significantly reduced SB in-stent restenosis in patients treated
with the culotte technique.
In PCI, bifurcation lesion treatment without stenting or
with BMS used to be associated with high risk of complica-
tions and restenosis.1–4 The use of drug eluting stents and
introduction of different bifurcations stenting strategies and
techniques resulted in marked improvements.5,6,12 Thus, the
recently published ARTS II study20 had similar event rates in
bifurcation and nonbifurcation lesions. At present, a strategy
of optional SB stenting, where the SB is stented only in case
of severe stenosis or flow problems after MV stenting, has
been found to be safe and efficient in registries and random-
ized clinical and angiographic trials.5,11,12,21 However, it is
still an open question if the strategy of optional SB stenting
Table 4. Results of Quantitative Angiography in the Three Bifurcation Segments
Variable
Proximal MV Segment Distal MV Segment Side Branch
Crush n160 Culotte n164 P Crush n160 Culotte n164 P Crush n160 Culotte n164 P
In-stent* minimal luminal diameter, mm
Before 1.910.77 1.810.79 0.27 1.530.66 1.480.70 0.55 1.450.64 1.390.66 0.47
After 3.180.54 3.140.55 0.44 2.570.48 2.560.46 0.97 2.250.49 2.280.44 0.57
Follow-up 3.020.55 3.020.55 0.96 2.340.50 2.370.52 0.60 2.040.65 2.080.48 0.57
In-stent* reference diameter, mm
Before 3.040.66 3.010.65 0.68 2.590.55 2.490.60 0.12 2.390.55 2.380.58 0.93
After 3.510.55 3.440.52 0.23 2.870.50 2.870.47 0.89 2.640.58 2.610.49 0.69
Follow-up 3.410.51 3.350.51 0.27 2.820.51 2.800.46 0.75 2.570.55 2.540.49 0.53
In-stent* diameter stenosis, %
Before 36.3322.51 39.6023.31 0.21 40.4822.75 40.5723.61 0.97 38.9923.11 41.9223.35 0.27
After 9.168.22 8.5410.21 0.56 10.4310.59 10.369.42 0.95 13.7912.78 12.2210.93 0.25
Follow-up 11.509.18 9.6010.89 0.10 16.2214.11 14.9713.66 0.43 20.3621.04 17.2915.32 0.14
In-stent* late lumen loss, mm
0.170.50 0.120.42 0.36 0.220.52 0.190.49 0.60 0.210.58 0.200.48 0.89
Edge minimal luminal diameter (mm)
After 3.140.65 3.080.62 0.41 2.200.49 2.160.46 0.52 1.990.53 1.980.46 0.98
Follow-up 3.000.64 3.040.64 0.50 2.170.49 2.160.50 0.87 1.990.53 1.990.46 0.95
Restenosis, n (%)
In-stent 0 0 … 3 (2.0) 1 (0.6) 0.31 15 (9.8) 6 (3.8) 0.04
Edge 3 (2.0) 0 (0) 0.08 1 (0.7) 2 (1.3) 0.57 3 (2.0) 2 (1.3) 0.64
*In-stent segments included the stented areas of the main vessel and the stent/balloon-treated areas of the side branch; if the side branch was not treated, the
parameters included the first 5 mm of the side branch.
Restenosis 50% diameter stenosis at 8-months follow-up.
Fisher’s exact test or Student’s t test were used.
SB indicates side branch; MV, main vessel.
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Figure 3. Rates of in-segment restenosis in crush vs culotte-
treated bifurcation lesions. Restenosis, 50% diameter stenosis
at 8 months follow-up. MVSB, main vessel and/or side
branch; MV, main vessel; SB, side branch. Fisher’s exact test
was used.
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should be the preferred treatment in all bifurcation lesions,
especially if the bifurcation lesion encompasses a large SB or
there is a long lesion of the SB.
We selected crush and the culotte bifurcation techniques
for the present evaluation. These techniques are dedicated
bifurcation techniques aiming at full stent coverage of the
bifurcation lesion, based on extensive documentation of low
in-stent restenosis rates in DES-treated lesions.18
The culotte technique was described by Chevalier et al15
using BMS. Originally, they recommended to stent the
branch with the sharpest angle first, usually the SB, and then
stent the other vessel through the first stent. This resulted in
2 layers of stent proximal to the bifurcation, full coverage of
the bifurcation region and of both branches distal to the
bifurcation. Because of technical complexity, high rates of
procedural events, and restenosis in the BMS era, the tech-
nique was infrequently used. In the DES era, the technique
was reintroduced with promising results in observational
studies16 and in the Nordic Bifurcation Study.11 The present
study recommended stenting of the MV first to avoid acute
closure of the MV and showed that culotte stenting could be
performed with excellent short- and medium-term results.
The crush technique, introduced by Colombo et al14 also
ensures complete lesion coverage at the SB ostium. As a
modified T-stenting technique, the SB stent is deployed 2 to
3 mm proximal to the bifurcation within the MV and
thereafter crushed by a stent or a balloon in the MV. The
crush technique ensures flow in both MV and SB, but the 3
layers of stent proximal to the SB ostium has been a concern.
Therefore, in the present study we recommended positioning
of the SB stent with its proximal end in the middle of the MV
to avoid extensive areas with multiple stent layers. In regis-
tries and a randomized trial, restenosis rates of 12% to 28%
have been reported after crush stenting.5,19 Our in-segment
restenosis rate of 12.1% compares favorably with these
results, possibly because there was a per protocol kissing
balloon postdilatation. A final kissing balloon dilatation has
been related to low restenosis rates in bifurcation lesions
using crush and other bifurcation stenting techniques.22
Crush Versus Culotte Bifurcation Technique
It is noteworthy that both techniques were associated with
excellent clinical and angiographic results. Procedure com-
plexity as assessed by procedure time, fluoroscopy time, and
contrast use was similar in the 2 groups. There was a higher
success rate of final kissing balloon dilatation in culotte-
treated patients, probably because rewiring and balloon in-
sertion through stent struts are more difficult in the crush
technique, where 3 layers of stent have to be crossed versus
only 1 layer in the culotte technique. This might be an
explanation for the higher rate of angiographic SB in-stent
restenosis in the crush group. Both techniques had a very high
procedural success rate without any difference between
groups. This suggests that the 2 procedures are technically
equally demanding and probably also reflects high operator
skill and dedication. Interestingly, SB predilatation was used
significantly more often in the culotte group. This may reflect
that there were more SBs with significant preprocedure
stenosis, or that operators were more prone to perform a
proper dilatation of the SB in culotte lesions to facilitate
crossing with the SB stents.
Clinical Implications
According to our results and those of others,5,6,11 PCI with
implantation of SES seems to be the treatment of choice in
bifurcation lesions. SES in these lesions have reduced com-
plication rates and rates of clinical and angiographic resteno-
sis to the same level as in less complex coronary artery lesion
subsets.20
Several authors have advocated the simple strategy in
percutaneous bifurcation treatment with stenting of MV and
provisional SB stenting.13 Our results do not contradict these
recommendations, but show that dedicated 2-stent techniques
can be used by experienced operators with excellent results.
Therefore, 2-stent strategies may be considered when SB
restenosis should be avoided, ie, in large SBs, where reste-
nosis is likely to result in clinical problems.
Both the crush and the culotte bifurcation strategy were
associated with excellent clinical and angiographic results.
On the basis of the present study results, 1 of the 2 techniques
studied cannot be claimed superior to the other. This choice
should be based on operator experience and the lesion
characteristics.
Study Limitations
This study had an open design with operators and patients
being aware of the technique used. MACE, however, was
adjudicated by a blinded event committee and should not be
influenced by the open design of the study. The study was
considerably underpowered given the observed MACE rate.
A properly powered study would include 15 000 patients.
An inclusion of this order of magnitude would not be feasible
in the complex lesion subset of the present study. The patients
studied were operator selected, and there was a large center
difference in inclusion of patients, from less than 5% to more
than 50% of eligible patients. Also, it is likely that patient
selection included feasibility for both treatment modalities.
Therefore, the overall recommendation from the study may
not be valid for all bifurcation lesions and operators. Further-
more, although the rates of MACE and significant angio-
graphic stenosis were low after 6 months clinical and 8
months angiographic follow-up, the durability of these results
on a long-term basis is not known.
Conclusions
In conclusion, excellent 6 months clinical and 8 months
angiographic results can be obtained with the crush and
culotte stenting of de novo coronary artery bifurcation lesions
using SES. Culotte-stented lesions tended to have lower
angiographic restenosis rates making this technique an attrac-
tive bifurcation stenting technique in feasible bifurcation
lesion anatomies.
The 6 months clinical results and the 8 months quantitative
coronary angiography results of the trial were presented as
late breaking clinical trials at the Transcatheter Cardiovascu-
lar Therapeutics meeting, October 2007 and at the annual
meeting of the American College of Cardiology in Chicago,
March 2008.
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Appendix
The Nordic-Baltic PCI Study Group: The purpose of the Nordic
PCI Study Group is to conduct academic randomized clinical trials
and to optimize PCI treatment in the Nordic and Baltic countries.
Steering committee members are as follows: Leif Thuesen, Aarhus
University Hospital, Skejby, Aarhus, Denmark; Jens Flensted Las-
sen, Aarhus University Hospital, Skejby, Aarhus, Denmark; Jens
Aarøe, Aalborg University Hospital, Aalborg, Denmark; Per Thay-
ssen, Odense University Hospital, Odense, Denmark; Steffen
Helqvist, Rigshospitalet, Copenhagen, Denmark; Jan Skov Jensen,
Gentofte University Hospital, Gentofte, Denmark; Anders Galløe,
Gentofte University Hospital, Gentofte, Denmark; Stefan James,
Uppsala University Hospital, Uppsala, Sweden; Iwar Sjo¨gren, Falun
Hospital, Falun, Sweden; Terje Steigen, University Hospital of
Tromsoe, Tromsoe, Norway; Jan Mannsverk, University Hospital of
Tromsoe, Tromsoe, Norway; Oliver Meyerdierks, Ullevaal Univer-
sity Hospital, Oslo, Norway; Pål Gunnes, The Feiring Clinic,
Feiring, Norway; Svein Rotevatn, Haukeland University Hospital,
Bergen, Norway; Rune Wiseth, St. Olav Hospital, Trondheim,
Norway; Kjell Nikus, Tampere University Hospital, Tampere, Fin-
land; Saila Vikman, Tampere University Hospital, Tampere, Fin-
land; Juha Hartikainen, Kuopio University Central Hospital, Kuopio,
Finland; Matti Niemela¨, Department of Internal Medicine, Univer-
sity of Oulu, Oulu, Finland; Kari Kervinen, Department of Internal
Medicine, University of Oulu, Oulu, Finland; Kari Virtanen, Hel-
sinki University Central Hospital, Helsinki, Finland; Juhani Airaksi-
nen, Turku University Central Hospital, Turku, Finland; Antti
Ylitalo, Satakunta Central Hospital, Pori, Finland; Andrejs Erglis,
Paul Stradins Clinical Hospital, Riga, Latvia; Indulis Kumsars, Paul
Stradins Clinical Hospital, Riga, Latvia.
Quantitative Coronary Angiography Core Laboratories: Aarhus
University Hospital, Skejby, Aarhus, Denmark; Michael Maeng and
Helle Hoejdahl. Paul Stradins Clinical Hospital, Riga, Latvia; Inga
Narbute.
Participating centers, primary investigators, and inclusions per
center: Denmark: Aarhus University Hospital, Skejby, Aarhus,
Primary investigator: Leif Thuesen (83 pts); Gentofte University
Hospital, Primary investigator: Jan Skov Jensen (44 pts); Aalborg
University Hospital, Primary investigator: Jens Aarøe (3 pts); Rig-
shospitalet, Copenhagen, Primary investigator: Steffen Helqvist (11
pts); Odense University Hospital, Primary investigator: Per Thayssen
(14 pts). Norway: Tromsoe University Hospital, Primary investiga-
tor: Terje Steigen (15 pts); The Feiring Clinic, Oslo. Primary
investigator: Pål Gunnes (50 pts); Trondheim University Hospital,
Primary investigator: Rune Wiseth (4 pts). Finland: Oulu University
Hospital, Primary investigator: Matti Niemela¨ (87 pts); Tampere
University Hospital, Primary investigator: Saila Vikman (8 pts);
Helsinki University Hospital, Primary investigator: Kari Virtanen
(11 pts); Kuopio University Hospital, Primary investigator: Mikko
Puhakka (2 pts). Latvia: Paul Stradins Clinical Hospital, Riga,
Primary investigator: Andrejs Erglis (92 pts).
Coordination and data entry: Hanne Rask Hansen, study secretary,
Helle Bargsteen, study secretary, Dorthe Frydensberg, study nurse,
Marianne Esbjerg, study nurse. Data monitoring and safety: Mem-
bers of the steering committee. Statistical support: Leif Spange
Mortensen, MSc, UNI-C, Danish Information Technology Centre for
Education and Research. Clinical end-point committee: Kristian
Thygesen, MD, Aarhus University Hospital, Aarhus, Denmark. Kjell
Nikus, MD, Department of Cardiology, Tampere University Hospi-
tal, Finland.
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Supplemental Material 
 
The Nordic-Baltic PCI Study Group 
The purpose of the Nordic PCI Study Group is to conduct academic randomized clinical 
trials and to optimize PCI treatment in the Nordic and Baltic countries. 
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